For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Intellia Therapeutics Inc (NASDAQ: NTLA) closed at $17.99 up 1.93% from its previous closing price of $17.65. In other words, the price has increased by $1.93 from its previous closing price. On the day, 1.85 million shares were traded. NTLA stock price reached its highest trading level at $18.15 during the session, while it also had its lowest trading level at $17.43.
Ratios:
For a deeper understanding of Intellia Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.21 and its Current Ratio is at 7.21. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on February 23, 2024, Downgraded its rating to Neutral and sets its target price to $32 from $136 previously.
On April 13, 2023, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $66.Canaccord Genuity initiated its Buy rating on April 13, 2023, with a $66 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 02 ’24 when Dube Michael P sold 2,012 shares for $19.01 per share. The transaction valued at 38,248 led to the insider holds 47,012 shares of the business.
Clark Eliana sold 405 shares of NTLA for $9,287 on Jul 01 ’24. The EVP, Chief Technical Officer now owns 71,470 shares after completing the transaction at $22.93 per share. On Jun 17 ’24, another insider, Verwiel Frank, who serves as the Director of the company, sold 1,505 shares for $25.00 each. As a result, the insider received 37,625 and left with 17,948 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NTLA now has a Market Capitalization of 1827406208 and an Enterprise Value of 1242636544. For the stock, the TTM Price-to-Sale (P/S) ratio is 39.75 while its Price-to-Book (P/B) ratio in mrq is 1.82. Its current Enterprise Value per Revenue stands at 27.033 whereas that against EBITDA is -2.417.
Stock Price History:
Over the past 52 weeks, NTLA has reached a high of $34.87, while it has fallen to a 52-week low of $17.48. The 50-Day Moving Average of the stock is -19.16%, while the 200-Day Moving Average is calculated to be -28.12%.
Shares Statistics:
For the past three months, NTLA has traded an average of 1.42M shares per day and 1550860 over the past ten days. A total of 101.58M shares are outstanding, with a floating share count of 99.78M. Insiders hold about 1.77% of the company’s shares, while institutions hold 85.99% stake in the company. Shares short for NTLA as of 1726185600 were 14759250 with a Short Ratio of 10.37, compared to 1723680000 on 13820274. Therefore, it implies a Short% of Shares Outstanding of 14759250 and a Short% of Float of 16.56.
